Skip to main content Skip to footer
Algernon Health Inc
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Aug 05, 2020 1:57pm EDT

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Aug 05, 2020 8:37am EDT

Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil

Jul 21, 2020 8:00am EDT

Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment

Jul 16, 2020 8:00am EDT

Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19

Jul 07, 2020 8:00am EDT

Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

Jun 25, 2020 8:00am EDT

Algernon Receives Ethics Approval for U.S. Sites for 2b/3 Human Study of Ifenprodil for COVID-19

Jun 04, 2020 12:10pm EDT

Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

May 28, 2020 9:00am EDT

Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD

May 26, 2020 8:49am EDT

Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

May 25, 2020 8:00am EDT

Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2025 Algernon Health Inc. All Rights Reserved.
Privacy Policy Sitemap